Impacts of a Brazilian pharmaceutical program on the health of chronic patients.
Aléssio Tony Cavalcanti de AlmeidaEdvaldo Batista de SáFabiola Sulpino VieiraRodrigo Pucci de Sá E BenevidesPublished in: Revista de saude publica (2019)
The strategy to expand access to medicines through the PFPB was effective in reducing hospitalizations and deaths by hypertension and diabetes in Brazil during the investigated period. Better understanding the impacts of the program is important to improve the pharmaceutical care policy, to ensure access to cost-effective treatments.
Keyphrases
- healthcare
- public health
- blood pressure
- quality improvement
- mental health
- type diabetes
- ejection fraction
- newly diagnosed
- cardiovascular disease
- prognostic factors
- palliative care
- health information
- patient reported outcomes
- risk assessment
- mass spectrometry
- metabolic syndrome
- patient reported
- social media
- arterial hypertension